Also, regarding this issue, the presence of pre-operative ctDNA, assessed by ddPCR detecting BRAF and NRAS mutations, was detected in 34% of 119 patients with stage III melanoma who underwent CLND, and was significantly associated with tumor burden and worse MSS [81]. This evidence concerns the gene BRAF and melanoma.